A case of erectile dysfunction and risk factors for coronary artery disease.
The hypothetical case of a man with erectile dysfunction and multiple cardiovascular risk factors is presented to illustrate the use of the second Princeton Consensus Conference Guidelines. Methods to optimize efficacy of the phosphodiesterase inhibitors are described. The overall cardiovascular safety of the phosphodiesterase inhibitors and their interaction with organic nitrates and alpha blockers are discussed.
Kloner
R A
RA
Heart Institute, Good Samaritan Hospital and Division of Cardiovascular Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, 90017, USA. rkloner@goodsam.org
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000209:etiology*; D048909:Diabetes Complications / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy*; D015444:Exercise; D017408:Guidelines as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000209:etiology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011687:Purines; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones
D000806:Angiotensin-Converting Enzyme Inhibitors; D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases